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Impairment in the activity and expression of glutamate transporters has been found in experimental
models of epilepsy in adult animals. However, there are few studies investigating alterations on gluta-
mate transporters caused by epilepsy in newborn animals, especially in the early periods after seizures.
In this study, alterations in the hippocampal glutamate transporters activity and immunocontent were
investigated in neonatal rats (7 days old) submitted to kainate-induced seizures model. Glutamate
uptake, glutamate transporters (GLT-1, GLAST, EAAC1) and glutamine synthetase (GS) were assessed in
hippocampal slices obtained 12 h, 24 h, 48 h, 72 h and 60 days after seizures. Immunoreactivity for hip-
pocampal GFAP, NeuN and DAPI were assessed 24 h after seizure. Behavioral analysis (elevated-plus
maze and inhibitory avoidance task) was also investigated in the adult animals (60 days old). The
decrease on glutamate uptake was observed in hippocampal slices obtained 24 h after seizures. The
immunocontent of GLT-1 increased at 12 h and decreased at 24 h (+62% and 20%, respectively), while
GLAST increased up to 48 h after seizures. No alterations were observed for EAAC1 and GS. It should
be mentioned that there were no long-term changes in tested glutamate transporters at 60 days after kai-
nate treatment. GFAP immunoreactivity increased in all hippocampal subﬁelds (CA1, CA3 and dentate
gyrus) with no alterations in NeuN and DAPI staining. In the adulthood, kainate-treated rats showed anx-
iety-related behavior and lower performance in the inhibitory avoidance task. Our ﬁndings indicate that
acute modiﬁcations on hippocampal glutamate transporters triggered by a single convulsive event in
early life may play a role in the behavioral alterations observed in adulthood.
 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Epileptic seizures in children are a common and frightening
neurological condition. The incidence of seizures is signiﬁcantly
higher in children than in adults, with the highest incidence in
the ﬁrst year of life (Holmes and Ben-Ari, 2001). This higher sus-
ceptibility to seizure of immature brain compared to adult seems
to be related to the fact that c-aminobutiric acid (GABA), an inhib-
itory neurotransmitter in mammalian brain, exerts paradoxical
excitatory effects in early ages (Khazipov et al., 2004; Ben-Ari,
2002). Epidemiological data suggest that prolonged seizures or
status epilepticus (SE) in childhood may lead to increased risk of
epilepsy in adulthood, through mechanisms still unknown (Haut
et al., 2004).lsevier OA license. 
: +55 51 33085540.
eira).Glutamate is the main excitatory neurotransmitter in the
mammalian central nervous system (CNS), involved in essential
physiological brain functions, as synaptic plasticity, learning
and memory, brain development and ageing (Tzingounis and
Wadiche, 2007; Danbolt, 2001; Segovia et al., 2001; Ozawa
et al., 1998). Glutamate acts through activation of N-methyl-D-
aspartate (NMDA), a-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate (AMPA) and kainate ionotropic receptors, and
metabotropic receptors (for reviews see Kew and Kemp (2005),
Rothstein et al. (1996)). However, overstimulation of the gluta-
matergic system (by exogenous or endogenous stimuli), which
occurs when glutamate levels in the synaptic cleft increase over
the physiological range, is involved in various acute and chronic
brain diseases (excitotoxicity), including neurodegenerative dis-
eases, traumatic brain injury, cerebral ischemia, and seizures
(Tzingounis and Wadiche, 2007; Danbolt, 2001; Maragakis and
Rothstein, 2004; Beart and O’Shea, 2007; Sheldon and Robinson,
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concentrations is extremely important.
There are strong evidences pointing that glutamatergic excito-
toxicity may be prevented by astrocytic glutamate uptake, a pro-
cess responsible for maintaining the extracellular glutamate
levels below toxic levels (Rothstein et al., 1996; Chen and Swanson,
2003; Belanger and Magistretti, 2009). To date, ﬁve distinct high-
afﬁnity, sodium-dependent glutamate transporters have been
cloned from animal and human tissue [GLAST (EAAT1), GLT-1
(EAAT2), EAAC1 (EAAT3), EAAT4 and EAAT5], differing in molecular
structure, pharmacological properties, and tissue distribution
(Danbolt, 2001; Beart and O’Shea, 2007; Bunch et al., 2009; Dunlop,
2006). Immunohistochemical studies have revealed that GLAST
and GLT-1 are localized primarily in astrocytes, whereas EAAC1
is widely distributed in neurons (Danbolt, 2001; Dunlop, 2006).
The impairment of these glutamate transporters has been also
implicated in the pathophysiology of some brain disorders, as epi-
lepsy and seizures (Bjornsen et al., 2007; Binder and Steinhauser,
2006; Zhang et al., 2004; Ueda et al., 2001; Tanaka et al., 1997).
Glutamate, after being taken up into astrocytes, may be con-
verted to glutamine by glutamine synthetase (GS), which then is
released to extracellular space and taken up by neurons where it
is converted again to glutamate and stored in pre synaptic vesicles
(Danbolt, 2001; Suarez et al., 2002). Thus, the GS activity is an
essential step in the glutamate–glutamine cycle, and its impair-
ment has been implicated in pathogenesis of temporal lobe epi-
lepsy (TLE), since GS expression and activity is reduced in the
hippocampus of TLE patients (Eid et al., 2004). In adult animals,
GS was increased in the latent phase and decreased in the chronic
phase of kainate-induced seizures (Hammer et al., 2008).
The consequences of status epilepticus (SE) in the developing
brain appear to be different from those of mature brain. Compari-
sons of the ﬁndings obtained in the adult and newborn brain reveal
a paradox, in that the immature brain has generally been consid-
ered ‘resistant’ to the damaging effects of hypoxia and hypoxia–
ischemia, while at the same time exhibiting periods of heightened
sensitivity to injury, dependent on the speciﬁc developmental
stage of the brain (Holmes, 2005; Hurn et al., 2005).
Despite that, the immature brain is not immune to injury in
prolonged seizure as SE. Changes in AMPA receptors and EAAC1
transporter expression were reported in SE rats at 10 days post-
natal (P10) and these modiﬁcations were related to higher suscep-
tibility to another seizure episode (Zhang et al., 2004). Despite the
apparent low susceptibility of immature brain to seizure-induced
cell death, seizures in the developing brain can result in irrevers-
ible alterations in neuronal connectivity (Holmes and Ben-Ari,
2001). Neonatal rats, which suffered from SE displayed synaptic
alterations and memory impairment in the adulthood (Cognato
et al., 2010; Cornejo et al., 2007, 2008), showing that disturbances
in a critical period of brain maturation could persistently compro-
mise its function. Furthermore, neural injuries such as hypoxic or
hypoxic–ischemic insult to the developing brain will impact on
subsequent maturation, with long-lasting consequences for the
adult brain (Hurn et al., 2005).
Although some information is available regarding the involve-
ment of glutamate transporters in events triggered by seizure
activity in adult animals (Rothstein et al., 1996; Ueda et al.,
2001; Simantov et al., 1999; Miller et al., 1997), little is known
about the neonatal brain responses to seizure involving glutamate
transporters, especially in the early period post-seizure. The aim of
the present study was to investigate whether activity and immu-
nocontent of glial and neuronal glutamate transporters in the hip-
pocampus could be affected by kainate-induced seizure activity in
rat pups. Behavioral tasks (anxiety-related behavior and inhibitory
avoidance task) were also evaluated in adulthood (60 days after
the seizures period).2. Materials and methods
2.1. Kainate-induced seizure model
Wistar rats were maintained under controlled environment
(21–22 C, 12 h dark-light cycle, food and water at libitum). All
experiments were in agreement with the Committee on Care and
Use of Experimental Animal Resources of Federal University of
Rio Grande do Sul, Brazil. Seizures were induced as previously de-
scribed (Cornejo et al., 2007). Seven-day-old male Wistar rats were
separated from their dams and received a single injection of kai-
nate (KA) (1 mg/kg, s.c.) diluted in saline (NaCl 0.9 g%). Control ani-
mals received saline solution. The volume injected in each animal
corresponded to 1% of body weight (ml/g). All animals presented
seizures up to 30 min after KA injection. Seizures were character-
ized by intermittent myoclonic jerks, generalized tonic–clonic
jerks, scratching, ‘‘swimming’’, and ‘‘wet-dog shakes’’. After spon-
taneous ending of seizures (around 3 h after KA administration),
animals returned to their dams.2.2. [3H] Glutamate uptake
Hippocampal slices for glutamate uptake were obtained 12, 24,
48, 72 h and 60 days after the end of seizures episode. Animals
were euthanized, the hippocampi were dissected out and immedi-
ately immersed in ice-cold Hank’s balanced salt solution (HBSS)
containing (in mM): 137 NaCl; 0.63 Na2HPO4; 4.17 NaHCO3; 5.36
KCl; 0.44 KH2PO4; 1.26 CaCl2; 0.41 MgSO4; 0.49 MgCl2 and 1.11
glucose, pH 7.3. Slices from each hippocampus (0.4 mm) were ob-
tained using a McIlwain tissue chopper. They were pre-incubated
at 35 C for 15 min and the medium was replaced by HBSS. Gluta-
mate uptake was started by adding 100 lM [3H] glutamate. Incu-
bation was stopped after 5 min by aspiration of the medium and
slices were rinsed twice with ice-cold Na+-free HBSS. Slices were
then lysed in 0.5 N NaOH and kept overnight. The uptake was also
carried out in Na+-free HBSS (replaced by N-methyl-D-glucamine)
at 4 C. Sodium dependent uptake was considered as the difference
between the uptake with and without sodium. Incorporated radio-
activity was measured using a Wallac liquid scintillation counter.2.3. Western blotting
Hippocampi were dissected out 12, 24, 48, 72 h and 60 days
after the end of seizures episode and immediately homogenized
in a 25 mM HEPES solution (pH 7.4) with 0.1% SDS and protease
inhibitor cocktail (Sigma, USA). Samples (20 lg protein/well) were
separated in an 8% SDS–PAGE mini-gel and transferred to a
nitrocellulose membrane using a Trans-Blot system (Bio-Rad, São
Paulo/SP, Brazil). Membranes were processed as follow: (1)
blocking with 5% bovine serum albumin (Sigma, USA) for 2 h; (2)
incubation with primary antibody overnight: 1:1000 rabbit
anti-GLAST, rabbit anti-GLT-1 or rabbit anti-EAAC1 glutamate
transporters (AlphaDiagnostic International); 1:10,000 rabbit
anti-Glutamine synthetase (Sigma); 1:2000 mouse anti-b-Actin
(Sigma); (3) incubation with horseradish peroxidase-conjugated
secondary antibody for rabbit 1:3000 and mouse 1:3000 (Amer-
sham Pharmacia Biotech) for 2 h; (4) chemioluminescence (ECL,
Amersham Pharmacia Biotech, São Paulo/SP, Brazil) was detected
using X-ray ﬁlms (Kodak X-Omat, Rochester, NY, USA). The ﬁlms
were scanned and bands intensities were analyzed using Image J
software (developed at the US National Institutes of Health and
available on the web site (http://rsb.info.nih.gov/nih-image/). In
order to determine the adequate amount of protein to be assayed,
different protein concentrations were carried out in the same gel
for each antibody tested.
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Perfusion and ﬁxation of the brain from 4 animals/group were
performed 24 h after the end of seizures period through transcar-
diac perfusion with 4% paraformaldehyde and 0.25% glutaralde-
hyde, followed by cryoprotection in 30% sucrose solution
overnight. Brain was sectioned (50 lm coronal sections) using a
Leica VT1000S microtome (Leica Microsystems, São Paulo, Brazil).
Coronal sections were separated in 4 series throughout the dorsal
hippocampus with 300 lm interval between each section and col-
lected in PBS. Free-ﬂoating sections of rat brain were processed for
immunohistochemistry against the neuronal speciﬁc protein neu-
ronal nuclei (NeuN) and glial ﬁbrillary acidic protein (GFAP), using
a primary mouse anti-NeuN (1: 500, Chemicon International, São
Paulo/SP, Brazil) as well as rabbit anti-GFAP antibodies (1:500,
Dako, Denmark A/S). Antibodies were diluted in Tris buffer saline
(TBS, 0.5 M NaCl and 30 mM Tris, pH 7.4) containing 0.2% Triton
X-100 and 10% normal goat serum and incubated for 48 h at 4 C.
After incubation, sections were rinsed 4 times for 10 min in TBS
and subsequently incubated with secondary ﬂuorescent antibodies
overnight: Alexa ﬂuor anti-rabbit 488 and anti-mouse 594 (1:500,
Invitrogen, Porto Alegre/RS), in 0.1 M TBS containing 0.2% Triton X-
100 and 10% normal goat serum for 24 h at 4 C. After rinsing 4
times for 10 min in TBS, the sections were mounted on slides
coated with 2% gelatin with chromium and potassium sulfate.
The slices were mounted in a Vectashield mounting medium con-
taining the nuclear marker DAPI (40-6-diamidino-2-phenylindole
dilactate) (Vector Laboratories, São Paulo/SP, Brazil). The CA1,
CA3 and dentate gyrus (DG) subﬁelds of each hippocampus were
examined in the Olympus FluorView 1000 system and the ﬂuores-
cence was quantiﬁed using ImageJ software. The images were cap-
tured and a square region of interest (ROI) was created considering
the pyramidal layer size. The ROI square of 8019 lm2 was overlaid
on the analyzed subﬁelds with blood vessels and other artifacts
being avoided, using a magniﬁcation of 20x. Six ROI were analyzed
per subﬁeld.2.5. Behavioral analysis
2.5.1. Elevated plus-maze task
Rats (60-day-old) were exposed to the elevated plus-maze
apparatus that consisted of a central platform (10 cm  10 cm)
with 2 open and 2 closed arms (45 cm  10 cm), arranged in such
a way that the 2 arms of each type were opposite to each other. The
apparatus was kept 88 cm above the ﬂoor and sessions were car-
ried out in a room lighted only with a dim red light. Animals were
individually placed in the central platform facing an open arm and
observed for 5 min. Two observers blinded to treatments recorded
the number of entries and the time spent in the open arms as mea-
surements of anxiety-related behavior (Walf and Frye, 2007).Fig. 1. Effects of a single episode of neonatal seizures on the hippocampal [3H]
glutamate uptake. Hippocampal slices were obtained at 12, 24, 48 and 72 h and 60
days post-seizures. Data are expressed as mean ± SD from 6 animals/group.
⁄P < 0.05, signiﬁcant difference from control group within the time analyzed
(One-way ANOVA followed by Tukey’s post-hoc test).2.5.2. Inhibitory avoidance task
Rats (60-day old) were placed on a 5.0 cm-high, 8.0 cm-wide
platform located in the left side of a 50 cm  25 cm  25 cm inhib-
itory avoidance task apparatus, with ﬂoor composed by a series of
parallel bronze bars 1.0 cm apart. In the training session, the la-
tency to step down from the platform to the grid with all four paws
was measured; immediately after stepping down onto the grid ani-
mals received a 0.4 mA, 1.0-s scrambled foot shock. The test ses-
sion was performed 1.5 h (short-term memory) and 24 h (long-
termmemory) after training and procedures were the same, except
that the foot shock was omitted. Differences between training and
test latencies to step down were taken as an index of memory.2.6. Statistical analysis
For glutamate uptake, western blot data and immunohisto-
chemistry, the results were expressed as mean ± standard devia-
tion, and statistical analysis was performed by one-way ANOVA
followed by Tukey’s test as post-hoc. For elevated plus maze task,
the results were expressed as mean ± standard deviation and the
Student’s t test was applied. For inhibitory avoidance task, the re-
sults were expressed as median ± interquartile range andWilcoxon
test was used for analysis within groups. For statistical signiﬁ-
cance, the value of P < 0.05 was adopted. The statistical analysis
was performed using SPSS 15.0 software.
3. Results
3.1. Effect of kainate-induced seizures on hippocampal glutamate
uptake activity and on glutamate transporters immunocontent
Fig. 1 shows that the glutamate uptake by hippocampal slices
obtained 12 h after kainate-induced seizures showed a trend to
be higher (P = 0.082), and those obtained 24 h after seizures de-
creased 20%, when compared to control group. Glutamate uptake
by hippocampal slices was not affected by seizures after 48 h.
The immunocontent of astrocytic glutamate transporters (GLAST
and GLT-1) and of neuronal glutamate transporter (EAAC1) was
determined in the whole hippocampus obtained 12, 24, 48, 72 h
and 60 days after seizures (Fig. 2). GLT-1 increased (37%) in hippo-
campi obtained 12 h after the seizures period, followed by a de-
crease (20%) at 24 h (Fig. 2A). GLT-1 showed no alterations after
48 h. The immunocontent of GLAST increased around 2 fold in hip-
pocampi obtained from KA group only up to 48 h after seizures
(Fig. 2B). The immunocontent of the neuronal EAAC1 glutamate
transporter was not affected by KA-induced (Fig. 2C). We next
investigated the long-term modiﬁcations of the density of gluta-
mate transporters in the hippocampus; in 60-day-old rats the
GLT-1 and GLAST immunocontent increased, and the EAAC1
immunocontent decreased, compared with younger animals. How-
ever, there was no difference between the immunocontent of GLT-
1, GLAST or EEAC-1 in kainate-treated compared to control rats at
60 days of age. Additionally, the immunocontent of hippocampal
glutamine synthetase (GS) was not affected by KA-induced sei-
zures at any time point investigated (Fig. 3).
3.2. Effect of kainate-induced seizures on hippocampal GFAP
immunoreactivity
As the hippocampal glutamate uptake and the immunocontent
of astrocytic (GLT1 and GLAST) glutamate transporters were
Fig. 2. Effects of a single episode of neonatal seizures on the immunocontent of the glutamate transporters (GLT-1, GLAST and EAAC1), analyzed at 12, 24, 48 and 72 h and 60
days post-seizure. Control (black bars) and kainate (KA, white bars). Data are expressed as mean ± SD from 6 animals/group. At the top of the ﬁgure are representative images
of the immunocontent of transporters. b-Actin was used as a protein loading control. ⁄P < 0.05, signiﬁcant difference from control group within the speciﬁc time. #P < 0.05,
signiﬁcant differences within the group from other times analyzed; &P < 0.05, signiﬁcant difference from K72h (One-way ANOVA followed by Tukey’s post-hoc test).
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sode, immunohistochemical analysis for GFAP, NeuN and DAPI
was performed in this time in all subﬁelds of the hippocampus
[CA1, CA3 and dentate gyrus (DG)]. There was an increase in the
GFAP immunoreactivity in KA group as compared to control group
in all subﬁelds (Fig. 4). In the regions surrounding pyramidal layer
(SPL) and over pyramidal layer (PL) of CA3 there was an increase of
147% and 100% for GFAP immunoreactivity compared to control
group, respectively (Fig. 4; ﬁrst panel). Likewise, surrounding pyra-
midal layer (SPL) and over pyramidal layer (PL) of CA1 there was an
increase of 100% and 40% for GFAP immunoreactivity compared toFig. 3. Effects of a single episode of neonatal seizures on the immunocontent of
glutamine synthetase (GS). GS immunocontent was analyzed at 12, 24, 48 and 72 h
and 60 days post-seizure. Control (black bars) and kainate (KA, white bars). Data are
expressed as mean ± SD from 6 animals/group. At the top of the ﬁgure are
representative images of the immunocontent of GS. b-Actin was used as a protein
loading control.control group, respectively (Fig. 4; second panel). GFAP immunore-
activity increased 100% compared to saline-treated rats in the den-
tate gyrus (DG) (Fig. 4; third panel). NeuN immunoreactivity and
DAPI staining were similar between both groups, indicating ab-
sence of neuronal loss 24 h after seizure (data not shown).
3.3. Kainate-induced seizures caused anxiety-like behavior and
aversive memory impairment in adulthood
Sixty days after the seizures episode, male rats were submitted
to behavioral tasks. In elevated plus-maze task, aiming to assess
anxiety-related behavior (Fig. 5), kainate-treated rats presented a
decrease on the time spent and the number of entries in open arms
compared to saline-treated rats (Fig. 5). Kainate-treatment abol-
ished the short- (1.5 h after training) and long- (24 h after training)
term memory, evaluated in an inhibitory avoidance task (Fig. 6).4. Discussion
The present study shows that rats presenting KA-induced sei-
zures in early periods of development presented brain acute
molecular and biochemical alterations related to the glutamatergic
system, and long-term behavioral impairment in adulthood.
The short-term effects investigated were on hippocampal gluta-
mate uptake and on astrocytic glutamate transporters immuno-
content. At 12 h after seizures, there was an increase in the
glutamate uptake (that did not reach statistical signiﬁcance) and
in both GLT-1 and GLAST immunocontent. At 24 h after seizures,
the GLAST levels remained up regulated, while the glutamate up-
take activity and the GLT-1 levels became diminished. The EAAC1
and glutamine synthetase levels did not vary.
Fig. 4. Immunohistochemistry analysis for GFAP, NeuN and DAPI in the rat hippocampus after a single episode of neonatal seizures. GFAP, NeuN and DAPI reactivities were
evaluated 24 h after kainate-induced seizures. Fluorescence quantiﬁcation was achieved at the regions surrounding pyramidal layer (SPL) and over pyramidal layer (PL),
except for dentate gyrus (DG), using pictures acquired in 20x of magniﬁcation. Control (black bars) and kainate (KA, white bars). Data are expressed as mean ± SD from 4
animals per group. ⁄P < 0.005; signiﬁcant difference from control group (Student’s t-test).
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seems to be responsible for the transient increase and further de-
crease on glutamate uptake observed in the hippocampus obtained
12 and 24 h after the end of seizures, respectively. Considering that
in the forebrain regions, it was demonstrated that GLT-1 accounts
for more than 95% of the total high-afﬁnity glutamate uptake
capacity by cerebrocortical synaptosomal preparation and it is
the most abundant in CNS (Tanaka et al., 1997; Chao et al.,
2010), this correlation may embody a relevant pathophysiological
response to seizures (Ueda et al., 2002). Previous study had already
been conducted on the expression of glutamate transporters fol-
lowing kainate treatment during brain development and no differ-
ences were found for hippocampal GLT-1 mRNA levels 4, 8 and
16 h after kainate-induced seizures in rats at 7 days old (Simantov
et al., 1999). These differences between the studies could be due to
the required time course for changes in the mRNA expression(measured in the Ref. Simantov et al., 1999) and in the detection
on the translated protein (measured in our study). Interestingly,
GLAST was the only glutamate transporter in newborn rats treated
with kainate that remains up regulated and the same proﬁle for
GLAST mRNA levels was also observed in adult animals (Nonaka
et al., 1998). Additionally, it is noteworthy that the glutamate up-
take apparently follows the ontogeny of GLT-1 during brain devel-
opment (Ullensvang et al., 1997). Although it remains to be
determined if glutamate uptake in acutely isolated slices from rat
pups could be related to nerve terminals, glial cells or both cellular
compartments, a recent study reported that the uptake activity
into acutely dissociated slices from adult animals was related to
nerve terminals rather than glial uptake (Furness et al., 2008).
More investigations need to be performed helping to elucidate this
topic. Our ﬁndings ruled out the participation of EAAC1 transporter
in the kainate-induced seizures in newborns. Interestingly, the
Fig. 5. Behavioral performance in adult rats submitted to a single episode of
neonatal seizure. Animals were exposed to 5 min of exploration in the elevated
plus-maze. (A) Time spent in seconds (s) in the open arms; (B) number of entries in
the open arms. Data are expressed as means ± SD from 10 animals per group.
⁄P < 0.05; signiﬁcant difference from control group (Student’s t-test).
Fig. 6. Performance in the inhibitory avoidance task in adult rats submitted to a
single episode of neonatal seizure. Data are expressed as median ± interquartile
range (n = 10 per group) of the latencies to step down in seconds (s) in the training
and test session performed 1.5 h (short-term memory) and 24 h (long-term
memory) later. ⁄P < 0.05; signiﬁcant difference from training and test session
within group (Wilcoxon test).
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induced seizures, since hippocampal EAAC1 mRNA expression re-
mains increased up to 5 days after seizures (Nonaka et al., 1998).
As the kainate toxicity depends on the release of endogenous
excitatory amino acids (Ben-Ari, 1985; Coyle, 1983; Sperk et al.,
1983) and in vitro studies indicated that glutamate stimulates glu-
tamate transport in primary astrocyte cultures (Gegelashvili et al.,
1996), it can be hypothesized that the transient up regulation of
both transporters could reﬂect an attempt to remove the excess
of extracellular glutamate that accumulate during seizure periods
(Ueda et al., 2002). As the GLAST immunocontent was more specif-
ically involved in short (Duan et al., 1999) and prolonged (Gege-
lashvili et al., 1996) stimulatory effect triggered by glutamate on
its own uptake by cultured astrocytes, the longer lasting increase
in the GLAST immunocontent after KA-induced seizures here
observed (up to 48 h) could be interpreted as a neuroprotective re-
sponse to the increase of hippocampal glutamate extracellular
levels.
It is interesting to note that the increase in the immunoreactiv-
ity for GFAP-positive astrocytes, which was measured 24 h afterthe end of seizures, accomplished the increase in the GLAST immu-
nocontent. Epilepsy is characterized by hippocampal sclerosis,
which one striking hallmark is astrocytic ‘‘reactive gliosis’’, accom-
panied by neuronal cell loss, microvascular proliferation and syn-
aptic reorganization (Binder and Steinhauser, 2006; Seifert et al.,
2010). The occurrence of seizures affects astrocytes functions gen-
erating abnormal glutamatergic and GABAergic neurotransmission
activities, which precedes neuronal death (Kang et al., 2006).
Accordingly, it has been shown that kainate treatment caused
detectable cell damage 72 h after seizures, in 10 days old rats
(Dunleavy et al., 2010). The hippocampal damage can also be ob-
served in other seizure models in 15 days old animals (de Oliveira
et al., 2008; Sankar et al., 1998; Sperber et al., 1999). In our study,
astrogliosis was present in the hippocampus 24 h after seizures,
with no evident signs of neuronal damage; however, it cannot be
discarded the occurrence of neuronal damage after this time.
The ontogenetic proﬁle of glutamate transporters levels ob-
served in our ﬁndings is in agreement with previous data (Ullensv-
ang et al., 1997; Bar-Peled et al., 1997; Furuta et al., 1997), since
GLT-1 and GLAST levels increased, whereas EAAC1 decreased in
adult animals. Interestingly, seizures at 7-day old did not modify
the immunocontent of glutamate transporters in the adulthood.
It has been reported that patients with medical intractable me-
sial temporal lobe epilepsy (MTLE) present deﬁciency in the hippo-
campal glutamine synthetase (GS) Eid et al., 2004. Likewise,
animals treated with methionine sulfoximine, which leads to deﬁ-
ciency in the GS activity, presented recurrent seizures, hippocam-
pal atrophy and neuronal loss (Eid et al., 2008). These ﬁndings
suggest that GS may play a role in the pathogenesis of MTLE that
could contribute to glutamate accumulation observed in this con-
dition. In our study, GS hippocampal levels were not affected by
kainate-induced seizures.
Even though the short-term alterations in the hippocampal
glutamatergic parameters were not persistent over time, in adult-
hood the rats presented anxiety-related behavior and memory de-
cline in an inhibitory avoidance task. Behavioral alterations caused
by kainate-induced seizure were investigated in other studies. The
performance in behavioral tasks was analyzed using different par-
adigms, and they indicated that poor memory performance is ob-
served in adulthood after seizure (Cognato et al., 2010; Cornejo
et al., 2007, 2008; Sun et al., 2009). These behavioral ﬁndings were
related to synaptic alterations, such as reduction of synaptic pro-
teins SNAP-25, syntaxin, PSD-95 and NMDA receptor (Cognato
et al., 2010; Sun et al., 2009). In our study, besides memory impair-
ment, we also observed anxiety-like behavior in adulthood after
seizure episode, although we recognize that this is not a common
ﬁnding compared to other studies (Cognato et al., 2010; Cornejo
et al., 2008). These long-lasting behavioral alterations might be re-
lated to early changes in hippocampal glutamatergic neurotrans-
mission. A previous study of our group also suggested that
alterations in early periods after birth could be involved in behav-
ioral deﬁcits in adulthood (Moreira et al., 2010). The exact mecha-
nism involved in the long-term effects of KA-induced seizures on
behavioral performance in adulthood is still unknown, but appears
to involve impairment of the long-term potentiation, enhanced
long-term depression and reduction on synaptic proteins levels
(Cognato et al., 2010; Cornejo et al., 2007; Sun et al., 2009). Appar-
ently, astrogliosis is not persistent up to adulthood in this model
(Cognato et al., 2010).5. Conclusion
The early periods of brain development are of great relevance
and determine adequate brain function late in lifespan. Our study
indicates that a single convulsive event in early life could induce
J.D. Moreira et al. / Neurochemistry International 59 (2011) 217–223 223short-term alterations in relevant parameters involved in the
homeostasis of glutamatergic neurotransmission in the hippocam-
pus, which could be involved in the behavioral alterations in adult-
hood animals. Our ﬁndings can contribute to better understand the
role of glutamate transporters in seizures during childhood. From
clinical point of view, our data suggest that interventions on the
glutamatergic system during seizures in children may be relevant
for prevention of brain impairment in adulthood.
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